Xencor licenses Ab technology to Pfizer

Xencor, a US antibody discovery and development company, says that it  has entered into a technology license and evaluation agreement with  global drug behemoth Pfizer to optimize the performance of therapeutic  monoclonal antibodies. Pfizer will apply Xencor's proprietary Xtend  antibody half-life prolongation technology and XmAb ADCC enhancing  technology to its antibody drug candidates.

Under the terms of the agreement, Pfizer will have access to Xencor's  antibody optimization technology during a non-exclusive research period  for evaluation of the technology in several of its discovery projects.  In addition, the drug major has taken a commercial license to Xencor's  technology for one program.

Xencor will receive an upfront payment and is eligible to receive  additional consideration based on Pfizer's successful commercialization  of products that incorporate the technology. Further details of the  agreement were not disclosed.